Popular services
FOUNDAYO (ORFORGLIPRON) IN DUBAI
Explore whether Foundayo fits your weight-management needs through a clinical assessment. MyCare helps you start the review process; an enquiry does not guarantee prescription eligibility, medicine availability or a particular result.
WHAT IS FOUNDAYO?
Foundayo is the brand name for orforglipron, a non-peptide GLP-1 receptor agonist taken by mouth once a day. It is registered in the UAE for chronic weight management in eligible adults, alongside a reduced-calorie diet and increased physical activity.
An oral format is one factor in the decision. A doctor must also review your health history, current medicines, previous treatment and follow-up needs. Explore MyCare’s weight-management programme to understand the broader assessment pathway.
THE DECISION COMES BEFORE THE PRESCRIPTION
WHO MAY BE CONSIDERED
Foundayo may be considered for adults living with obesity, or some adults who are overweight and have a weight-related medical condition. BMI alone does not tell the whole story.
A clinician needs to understand previous treatment, current medicines, symptoms, medical history and what sustainable progress would look like for you.
The assessment is designed to identify both suitability and reasons another pathway may be safer or more appropriate.
A prescription should follow a clinical decision—not replace one.
If Foundayo is prescribed, the plan should also cover nutrition, hydration, side-effect management, progress review and what happens if treatment needs to change.
Previous conditions, procedures and family history can change whether treatment is appropriate.
The doctor should review prescriptions, supplements and any other GLP-1 medicine you may already use.
Blood pressure, cholesterol, blood sugar and other health factors may shape the clinical pathway.
Monitoring tolerance, nutrition and progress matters after treatment begins.
Good weight-management care is not about finding the newest medicine. It is about finding an appropriate plan and supporting it properly.
THE MYCARE PATHWAY
Prepare your medical history, medicine list and previous weight-management records for the assessment. Ask the team to clarify consultation, medicine and follow-up arrangements and costs. The clinical recommendation comes after the doctor’s review.
SAFETY INFORMATION
Common effects reported by Lilly include nausea, constipation, diarrhoea, vomiting, indigestion, abdominal pain, headache, bloating, tiredness, belching, heartburn, gas and hair loss.
Seek medical advice promptly for severe or persistent symptoms. Severe abdominal pain that does not go away may require urgent assessment for pancreatitis.
FOUNDAYO DUBAI FAQS
Straight answers about Foundayo, orforglipron, prescription requirements, suitability and doctor-guided support in Dubai.
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist. It is a prescription medicine used with reduced-calorie nutrition and increased physical activity for chronic weight management in eligible adults.
The Emirates Drug Establishment registered Foundayo in the UAE in April 2026. Access still requires a valid prescription and depends on clinical suitability and licensed-pharmacy availability.
It may be considered for adults with obesity, or some adults who are overweight and have a weight-related medical condition. A doctor must review BMI, health history, current medicines and individual risks before deciding whether it is appropriate.
Foundayo is taken by mouth once daily, with or without food, exactly as prescribed. Tablets should be swallowed whole. Do not change the dose or restart after a prolonged interruption without speaking to the prescribing clinician.
Foundayo contains orforglipron and is an oral tablet. Other GLP-1 medicines may contain different active ingredients and use weekly injections or different oral instructions. Convenience does not determine suitability; the decision should be based on medical assessment.
Common effects reported by the manufacturer include nausea, constipation, diarrhoea, vomiting, indigestion, abdominal pain, headache, bloating, tiredness, belching, heartburn, gas and hair loss. Discuss expected effects and warning signs with your doctor before treatment.
Use with another GLP-1 receptor agonist is not recommended. Tell the doctor about every medicine and supplement you use before treatment is considered.
Start with MyCare’s GLP-1 eligibility assessment or contact the care team on WhatsApp. A licensed doctor can review whether Foundayo or another pathway is clinically appropriate. Medication is prescribed only when suitable.
Prepare your weight history, previous weight-management treatments, current medicines and supplements, allergies and any recent medical reports. Tell the clinician what you hope to achieve and what concerns you have. The assessment helps the doctor decide which pathway may be appropriate.
Ask the MyCare team about the assessment process and current arrangements. Confirm consultation, medicine and follow-up costs separately before proceeding. A website enquiry does not confirm pharmacy stock, prescription eligibility or a guaranteed treatment outcome.
No specific weight-loss result can be guaranteed. Discuss realistic goals, monitoring and follow-up with the assessing doctor through MyCare’s weight-management programme.
